Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387108 | 0.98 | POLB (0.57) | POLBOPRM1OPRK1KCNH2KAT6A | |
| Water SCHEMBL27641336 | 0.98 | POLB (0.53) | POLBOPRM1OPRK1KCNH2KAT6A | |
| SCHEMBL6063449 | 0.96 | OPRM1 (0.51) | POLBOPRM1OPRK1KCNH2KAT6A | |
| SCHEMBL9986991 | 0.92 | OPRM1 (0.54) | POLBOPRM1OPRK1KCNH2CHRNB4 | |
| SCHEMBL16902847 | 0.92 | OPRM1 (0.54) | POLBOPRM1OPRK1KCNH2CHRNB4 | |
| Resorcinol SCHEMBL5982627 | 0.92 | POLB (0.48) | POLBOPRM1OPRK1KCNH2KAT6A | |
| SCHEMBL16902846 | 0.89 | OPRM1 (0.52) | POLBOPRM1OPRK1KCNH2CHRNB4 | |
| SCHEMBL16902844 | 0.85 | POLB (0.54) | POLBOPRM1OPRK1KCNH2KAT6A | |
| SCHEMBL12760850 | 0.84 | OPRM1 (0.48) | POLBOPRM1OPRK1KCNH2CHRNB4 | |
| SCHEMBL13806374 | 0.84 | HRH1 (0.62) | POLBOPRM1OPRK1KCNH2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858217-B2 | Stabilization of terpenoids in cosmetic compositions | UNILEVER HOME & PERSONAL CARE USA DIVISION OF CONOPCO, INC. (US) | 2005-02-22 | — | — | US | claimed |
| US-20030185867-A1 | Stabilization of terpenoids in cosmetic compositions | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-10-02 | — | — | US | claimed |
| WO-2003080011-A1 | STABILIZATION OF TERPENOIDS IN COSMETIC COMPOSITIONS | UNILEVER PLC (GB) | 2003-10-02 | — | — | WO | claimed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11337908-B2 | Personal care compositions with cystine | CONOPCO, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200222293-A1 | PERSONAL CARE COMPOSITIONS WITH CYSTINE | CONOPCO, INC.,D/B/A UNILEVER (US) | 2020-07-16 | — | — | US | disclosed |
| CN-106470660-A | Stabilized skin care compositions containing nitrogen boranes | 荷兰联合利华有限公司 | 2017-03-01 | — | — | CN | disclosed |
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| WO-2011158149-A1 | 2-(3,5-DISUBSTITUTEDPHENYL)PYRIMIDIN-4(3H)-ONE DERIVATIVES | PFIZER INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-2177526-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
| EP-1592397-B1 | IMPROVED FORMULATION FOR SKIN-LIGHTENING AGENTS | WARNER LAMBERT CO (US) | 2010-03-31 | — | — | EP | disclosed |
| CN-100577623-C | Decolorizing agent | WARNER LAMBERT CO | 2010-01-06 | — | — | CN | disclosed |
| CN-101544542-A | Depigmentation agents | WARNER LAMBERT CO | 2009-09-30 | — | — | CN | disclosed |
| EP-1628945-B1 | DEPIGMENTING AGENTS | WARNER LAMBERT CO (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20060257340-A1 | Formulation for skin-lightening agents | NAIR XINA | 2006-11-16 | — | — | US | disclosed |
| CN-1747921-A | Decolorizing agent | WARNER LAMBERT CO (US) | 2006-03-15 | — | — | CN | disclosed |
| EP-1628945-A1 | DEPIGMENTING AGENTS | Warner-Lambert Company LLC (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004103940-A1 | DEPIGMENTING AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060257340-A1 | Formulation for skin-lightening agents | CUTA, ADH4, LRAT | POLB 3925/4885OPRM1 3518/4885OPRK1 1709/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | POLB 870/4885OPRM1 1955/4885OPRK1 2921/4885 |
| US-20030185867-A1 | Stabilization of terpenoids in cosmetic compositions | SQLE, CYP51A1, RBP4 | POLB 2089/4885OPRM1 4301/4885OPRK1 4426/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | POLB 870/4885OPRM1 1955/4885OPRK1 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.